ANUHPHRAnuh Pharma Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
Anuh Pharma Limited engages in the manufacture and sale of bulk drugs and chemicals in India. It offers active pharmaceutical ingredients, including macrolides, anti-TB, anti-bacterial, anti-asthmatics, anti-diabetics, intermediates, expectorant, quinolones, anti-malarial, anti-gout, anti-biotic, anti-platelet, and antihistamines; and corticosteroids, including anti-inflammatory, immunosuppressant, anti-pruritic, anti-mitotic. The company also develops products, such as coagulants, gastrointestinal, anti convulsants, and cholesterol drugs. It also exports its products. The company was incorporated in 1960 and is headquartered in Mumbai, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on ANUHPHR — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
The picture
- • Profit growth: 37.3% YoY
- • Debt/Equity: 0.00
- • Promoter holding: 72.9%
- • Golden cross setup: SMA50 above SMA200
- • Beta: 0.49
Bull case
- • Profit growth: 37.3% YoY
- • Debt/Equity: 0.00
- • Promoter holding: 72.9%
- • Golden cross setup: SMA50 above SMA200
Bear case
- • Revenue growth: 3.9% YoY
- • RSI: 36
- • MACD: bearish
- • 1-month return: -15.1%
Key risks
- • Momentum is fading versus the broader market
- • Revenue growth: 3.9% YoY
- • RSI: 36
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹4.17). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.